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Background: The advent of multiple molecular targets in advanced 
non–small-cell lung cancer (NSCLC) has brought new treatments, 
but also new logistic and technical considerations, to the clinician. 
The small size of endoscopic biopsies and the increasing number of 
relevant but uncommon markers has increased the need for rational 
approaches to molecular testing. We present the results of clinical 
preselection before EML4-ALK testing in a German NSCLC cohort.
Methods: Patients with stage IV NSCLC were included. Clinicians 
were encouraged to consider screening epidermal growth factor recep-
tor wild-type adenocarcinoma patients with a limited smoking history, 
relatively young age, or who had benefited from chemotherapy for a 
relatively long period. Break-apart fluorescence in situ hybridization 
using archived paraffin tissue was performed in a central facility.
Results: From April 2010 to September 2011 we included 61 
patients: mean age 56.6 years, 41% women, 90% adenocarcinoma, 
5% large-cell, and 5% squamous cell cancers. Only three patients 
had activating epidermal growth factor receptor mutations; 16.4% of 
patients were positive for EML4-ALK fusion. The anaplastic lym-
phoma kinase (ALK)-positive patients included 60% women, tended 
to be younger, had smoked less, and had received significantly more 
systemic therapy, on average 3.7 lines of treatment over 3 years, 
before ALK-testing compared with the ALK-negative patients. Long 
periods of progression-free survival were experienced by ALK-
positive patients treated with pemetrexed, vinorelbine, or cetuximab.
Conclusions: EML4-ALK fusion is uncommon, reported in about 5% 
of NSCLC patients; however, clinical preselection increased the yield of 
testing to 16.4%. EML4-ALK positive patients seem to have distinct clin-
ical features and show long responses to a number of systemic therapies.
Key Words: Non–small-cell lung cancer, EML4-ALK translocation, 
Biomarker, Crizotinib.
(J Thorac Oncol. 2014;9: 109–113)
The prognosis for patients with advanced non–small-cell lung cancer (NSCLC) remains very poor. For some 
patients, recent advances in the area of targeted biological 
therapies have led to new therapeutic options. Treatment with 
the epidermal growth factor receptor (EGFR) tyrosine kinase 
inhibitors (TKIs) erlotinib and gefitinib is associated with high 
response rates and long progression-free survival (PFS) in 
tumors harboring mutations in the EGFR gene, in particular, in 
exons 19 and 21.1 The discovery of fusion of the echinoderm 
microtubule-associated protein-like 4 (EML4) gene with the 
gene for anaplastic lymphoma kinase (ALK) in a small subset 
of NSCLC led to the development of targeted treatments for this 
patient population.2 The ALK TKI crizotinib has been licensed 
in the United States since 2011 and in Europe since 2012 
for the treatment of ALK-positive patients having advanced 
NSCLC with disease progression after first-line chemotherapy. 
However, the relative rarity of EML4-ALK fusion in NSCLC, 
reported to be between 1.8% and 7.5% in unselected American 
and European populations,3 has raised the issue of who, when, 
and how to screen for this molecular alteration. In addition to 
the challenges raised by the prospect of multiple immunohis-
tochemical and genetic tests in small biopsies, the logistics 
and reimbursement of molecular biological analyses remains 
problematic in Germany as in many other countries. Therefore, 
there is great need for rational approaches and sequential diag-
nostic algorithms for molecular testing in NSCLC.
This article describes the use of clinical criteria to 
increase the yield of EML4-ALK testing in an urban German 
NSCLC patient cohort, and compares the clinical characteris-
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for further systemic treatment after progression after or 
during first-line chemotherapy. EML4-ALK testing using 
break-apart fluorescence in situ hybridization was carried 
out within the context of a clinical trial sponsored by Pfizer 
Ltd. (EudraCT-Number 2009-012504-13) in a central molec-
ular pathology department by using archived formalin-fixed, 
paraffin-embedded tumor biopsies.
Clinicians were encouraged to recommend EML4-ALK 
testing for patients with clinical criteria thought to be associated 
with EML4-ALK fusion on the basis of published data. These 
criteria included a relatively young age at the time of diagno-
sis, relatively long survival under standard systemic therapies, 
female sex, absence of current or previous heavy cigarette 
smoking, adenocarcinoma histology, and absence of EGFR 
mutation. The availability of EML4-ALK testing as well as the 
clinical triggers for testing were announced to local clinicians 
at continuing medical education events as well as at weekly 
interdisciplinary tumor boards. The clinical criteria were pre-
sented as a guide to assist in the decision to test for EML4-ALK 
fusion; however, age and pack-year cutoffs were not given, and 
treating clinicians were permitted to refer patients for testing 
who did not fit one or more of the clinical criteria.
Clinical and pathological data were extracted from the 
patient charts and medical records retrospectively. All patients 
gave written informed consent. The study was approved by 
a central ethics committee in Heidelberg (Ethikkommission 
Medizinische Fakultät Heidelberg, reference number AFmu-
393/2009) as well as the local ethics committee at the University 
of Munich (Ethikkommission der Universität München).
Statistics and Data Analysis
GraphPad Software (GraphPad QuickCalcs; GraphPad 
Software, Inc., La Jolla, CA) was used for all statistical analy-
ses. Categorical variables were analyzed using Fisher’s exact 
test. Continuous variables were reported as means ± SD. All t 
tests were unpaired and two-sided and p values less than 0.05 
were considered significant.
RESULTS
ALK-Screening Can Be Integrated 
into Routine Clinical Care
Between April 2010 and September 2011 61 patients 
were enrolled in the study. Tumor samples from 55 patients 
(90.2%) could be tested for EML4-ALK fusion. EML4-ALK 
testing could not be carried out in six patient samples (9.8% 
of those enrolled). In two of these cases the analysis was not 
carried out because the patient died shortly after enrolment. 
In four patients the archived tissue biopsies contained insuf-
ficient tumor material or were unavailable for testing.
Preselection Using Clinical Criteria 
Increases the Yield of ALK Testing
Of the 61 patients enrolled, 10 EML4-ALK–positive 
tumors were identified (16.4% of the intention-to-treat pop-
ulation, 18.2% of those patients actually tested). Forty-five 
patients were found to be negative for EML4-ALK fusion.
The suggested clinical selection criteria resulted in a 
patient population enriched for younger patients, patients with 
adenocarcinoma and women. The average age at the time of 
first diagnosis was 56.6 years. Twenty-five patients (41.0%) 
were women. Almost all participants had adenocarcinoma 
histology (55 of 61; 90%), three had squamous cell tumors, 
and three had large-cell histology. Thirty-eight patients had 
documented EGFR-mutation analyses, of which all but three 
showed EGFR wild type. ALK translocations were identified 
in nine patients with adenocarcinoma and in one patient with 
large-cell lung cancer.
On average, the EML4-ALK–negative patients tended 
to be slightly older than those found to be EML4-ALK posi-
tive (57.0 ± 11.38 years compared with 51.2 ± 9.84 years; 
p = 0.14). EML4-ALK–negative patients tended to be men 
(28 men, 17 women, 62% male). In contrast, the majority of 
EML4-ALK–positive patients were women (6 of 10, 60%). 
Overall, 24% of the female patients and 11% of the male 
patients tested were ALK-positive.
There was a statistically significant difference in smok-
ing behavior between the ALK-negative and ALK-positive 
patients. The average history of cigarette smoking was 
24.5 ± 26.3 pack-years in the ALK-negative group compared 
with only 5.2 ± 12.11 pack-years in the ALK-positive group 
(p = 0.043).
Many ALK-Positive Patients 
Are Heavily Pretreated
The number of lines of therapy received by patients pre-
vious to ALK-testing and the time since first diagnosis were 
compared. Because of the selection criteria for ALK-screening, 
the patients included in this study were heavily pretreated, hav-
ing received an average of 2.7 lines of treatment (range, 0–7) 
for their lung cancer over an average of 1.6 years (range, 0–8 
years) before being tested for EML4-ALK. Nevertheless, even 
within this heavily pretreated population the ALK-positive 
patients had received significantly more lines of treatment than 
their ALK-negative counterparts (ALK-negative: 2.48 ± 1.47 
lines of treatment, ALK-positive: 3.7 ± 2.26 lines of treat-
ment; p = 0.041). In addition, the time since first diagnosis was 
significantly longer in the ALK-positive compared with the 
ALK-negative group (ALK-negative: 1.26 ± 1.57 years, ALK-
positive: 3.0 ± 3.06 years; p = 0.013).
There were no significant differences in stage at first 
diagnosis or in type of first-line treatment between the ALK-
positive and ALK-negative groups. Despite the longer time 
since first diagnosis and higher number of treatment lines in 
the ALK-positive group, there was no significant difference 
in performance status between the groups at the time of ALK 
testing. The mean Eastern Cooperative Oncology Group per-
formance status in ALK-positive patients was 0.71 ± 1.11 and 
in ALK-negative patients 1.15 ± 0.99 (p = 0.34). Table 1 com-
pares the ALK-positive and ALK-negative patient cohorts.
Response to Standard Systemic Therapies
There was a trend (p = 0.098) toward longer responses 
to systemic therapy in the ALK-positive compared with the 
ALK-negative patient groups. The longest period of PFS after 
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a systemic treatment in any line was 14.9 ± 9.0 months in the 
ALK-positive group and 9.9 ± 7.6 months in the ALK-negative 
group (p = 0.098).
Pemetrexed
Twenty-one ALK-negative patients and seven ALK-
positive patients were treated with pemetrexed before enrol-
ment in this study. PFS after treatment with pemetrexed either 
alone or in combination with other systemic therapy was 
significantly longer in the ALK-positive compared with the 
ALK-negative patients (ALK-positive: 11.9 ± 9.0 months, 
ALK-negative: 5.4 ± 4.5 months).
Vinorelbine
Two of the ALK-positive patients in this study experi-
enced long periods of PFS under treatment with vinorelbine. 
One patient was treated with carboplatin and vinorelbine 
in first line and remained progression free for 13 months. 
A second ALK-positive patient was treated with fifth-line 
oral vinorelbine dosed metronomically in a clinical trial and 
remained progression free for 25 months.
Cetuximab
One ALK-positive patient with stage IV adenocarci-
noma experienced an exceptionally long period of PFS (26 
months) under maintenance treatment with cetuximab as part 
of a clinical trial. This patients’ tumor did not show an EGFR 
mutation; however, strong EGFR expression was found by 
using immunohistochemistry.
Response to Crizotinib in ALK-Positive Patients
All 10 of the ALK-positive patients identified were 
treated with crizotinib, either as part of a clinical study or 
within a compassionate-use program. The period of clinical 
benefit under crizotinib ranged from 2 weeks to more than 
19 months. The clinical characteristics of the ALK-positive 
patients as well as their responses to treatment with crizotinib 
are summarized in Table 2.
DISCUSSION
In this study, screening for the EML4-ALK translo-
cation was carried out in a cohort of German patients pre-
selected based on clinical criteria. The cohort was enriched 
for adenocarcinoma patients, women, relatively young age, 
absence of heavy smoking, and EGFR wild-type. This clinical 
preselection resulted in a high yield of ALK-positive cases, 
with EML4-ALK translocations being identified in 10 of the 
61 patients (16.4%) tested.
To our knowledge this is the first report of preselec-
tion for ALK-screening using clinical criteria in a European 
patient population.
In unselected NSCLC patients the incidence of ALK 
translocation is low. A large retrospective Korean study 
found translocations in 3.8% of surgically resected specimens 
tested.4 The incidence in an American cohort of patients with 
adenocarcinoma was found to be 5.6%.5 In the present study 
preselection using clinical criteria resulted in a cohort sig-
nificantly enriched for ALK translocation. The preselection 
TABLE 1.  Characteristics of ALK-Positive and ALK-Negative Patients with NSCLC
All Patients ALK-Negative Patients ALK-Positive Patients p
Total n (%) 61 45 (73.8) 10 (16.4)
Sex n (%) ns
  Male 36 (59) 28 (62) 4 (40)
  Female 25 (41) 17 (38) 6 (60)
Age at first diagnosis (yr) 56.6 57.0 51.2 ns
Smoking history
  Never-smoker 16 (26) 10 (22) 6 (60%)
  Ever-smoker 25 (41) 18 (40) 3 (30%)
  Unknown 20 (33) 17 (38) 1 (10%)
Average pack-years 21.5 24.5 6.25 p = 0.0434
Histology n (%) ns
  Adenocarcinoma 55 (90) 41 (91) 9 (90)
  Squamous-cell carcinoma 3 (5) 3 (7) 0
  Large-cell lung cancer 3 (5) 1 (2) 1 (10)
Stage at first diagnosis 61 45 10
  I-II 3 2 1
  III 15 9 2
  IV 42 33 7
  Unknown 1 1 0
Time from first diagnosis to ALK testing (yr) 1.6 1.3 3.0 p = 0.0126
Lines of previous therapy before ALK testing 2.7 2.5 3.7 p = 0.0406
ECOG performance status at the time of ALK testing 1.2 1.1 0.7 ns
ns, not significant; ECOG, Eastern Cooperative Oncology Group; ALK, anaplastic lymphoma kinase; NSCLC, non–small-cell lung cancer.
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criteria used in this study were chosen based on evidence 
that ALK-positive lung cancer cases occur predominantly in 
patients with EGFR wild-type and Kirsten rat srcoma wild-
type adenocarcinoma,6 younger age, and in never smokers or 
light smokers.7 Somewhat higher rates of ALK translocation 
have also been reported in female patients4 and in certain his-
tological subgroups including adenocarcinomas with a solid 
histology and signet-ring cells.5,8 ALK translocations and 
EGFR mutations only very rarely coexist.9
Recent guidelines published jointly by the College of 
American Pathologists, International Association for the Study 
of Lung Cancer, and Association for Molecular Pathology do 
not recommend the use of clinical criteria to exclude patients 
with adenocarcinoma from ALK testing.10 Although the wide-
spread implementation of EGFR and EML4-ALK testing for 
all patients with adenocarcinoma of the lung is a clinically 
important goal, there are significant logistic and financial bar-
riers that continue to limit testing in many countries.11–13 In 
settings in which it is not yet possible to test all patients for 
molecular alterations, preselection based on clinical criteria 
may be of use in prioritizing patients for testing.
The current study found that ALK-positive patients had 
received significantly more and longer treatment before ALK-
testing than their ALK-negative counterparts. In addition, the 
ALK-positive patients had been living with lung cancer for 
longer than those who tested negative for the EML4-ALK 
translocation. Previous data have suggested that EML4-ALK 
translocation is not, in itself, prognostic for improved out-
comes in NSCLC. Paik et al.4 retrospectively tested over 700 
resected lung cancer specimens and identified ALK transloca-
tions in 3.8%. EML4-ALK translocation was not found to be 
prognostically relevant in these stage I–III patients. However, 
in advanced, metastasized NSCLC ALK translocations may 
be associated with a favorable prognosis14 in addition to 
being highly predictive of response to the ALK-TKI crizo-
tinib. Although the retrospective nature of the current analysis 
makes it impossible to draw firm conclusions, the finding that 
ALK-positive patients had lived on average more than 3 years 
with lung cancer before testing for ALK was initiated seems to 
corroborate previous findings that the EML4-ALK transloca-
tion is prognostically relevant in advanced disease.
The current study also identified several ALK-positive 
patients with exceptionally long periods of PFS under treat-
ment with systemic agents including pemetrexed, vinorelbine, 
and cetuximab. The present trial found that PFS after treatment 
with pemetrexed alone or in combination with other systemic 
chemotherapeutics resulted in significantly longer PFS in ALK-
positive compared with ALK-negative patients. Good responses 
to pemetrexed in ALK-positive lung cancer patients have been 
described in a number of recent studies. Lee et al.15 reported 
longer PFS under pemetrexed in Korean patients with ALK 
translocations compared with patients with EGFR mutations 
and wild-type patients. This was associated with low levels of 
thymidylate synthase mRNA in ALK-positive cases. Low thy-
midylate synthase expression in NSCLC has previously been 
associated with increased sensitivity to pemetrexed.16 Similar 
findings were reported by Camidge et al.17, who retrospectively 
examined a cohort of American NSCLC patients including 
19 ALK-positive cases and found significantly longer PFS on 
pemetrexed in the ALK-positive patients compared with the 
others. A recent publication questioned the association between 
ALK positivity and pemetrexed response, and suggested that 
smoking status may be a relevant confounder.18 Because the 
current study population included only one ALK-positive heavy 
smoker, an analysis of the relative responsiveness to pemetrexed 
based on smoking and ALK status was not possible.
In addition to prolonged responses to pemetrexed, two 
ALK-positive patients in the current study experienced unusu-
ally long responses to vinorelbine. One ALK-positive patient 
remained progression free on a study of metronomic daily 
oral vinorelbine for 25 months. To our knowledge, this is 
the first report of long PFS in ALK-positive patients treated 
with vinorelbine. Previous studies have shown overall sur-
vival of approximately 30 weeks for NSCLC patients treated 
with single-agent vinorelbine19 and approximately 8 months 
after first-line treatment with cisplatin and vinorelbine.20 
Numerous studies have suggested that low expression of class 










Duration of Clinical Benefit 
under Crizotinib




1 Female 0 45 Yes 8 Months Meningeosis carcinomatosa Cranial irradiation, 
intrathecal 
chemotherapy
2 Female n.d. 47 Yes 2 Weeks Pulmonary progression Palliation
3 Male 0 65 Yes 9 Months Pulmonary progression Pemetrexed
4 Female 5 66 Yes 3 Months Cerebral metastasis Crizotinib
5 Male 0 51 Yes >15 Months — —
6 Male 0 39 Yes 11 Months Liver metastasis n.d.
7 Female 5 44 Yes 15 Months Cerebral metastasis Docetaxel
8 Female 0 40 Yes >19 Months — —
9 Male 37 57 Yes >18 Months — —
10 Female 0 58 Yes >18 Months — —
ALK, anaplastic lymphoma kinase; n.d. = not documented.
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to vinorelbine in both NSCLC21 and mesothelioma.22 To our 
knowledge, the class III β-tubulin of ALK-positive lung cancer 
has not yet been described. Although the number of patients 
observed in this study was small, and the patients were selected 
based on clinical criteria, which may have positively influenced 
the overall prognosis, it seems warranted to further study the 
effectiveness of vinorelbine in ALK-positive patients.
One ALK-positive patient in the current study experi-
enced an exceptionally long period of PFS (26 months) under 
treatment with the EGFR antibody cetuximab. This patient 
was a heavy smoker until the time of first diagnosis (37 pack-
years), and was positive for the human immunodeficiency 
virus. To our knowledge this is the first report of prolonged 
response to cetuximab in ALK-positive lung cancer.
All 10 ALK-positive patients in the current study were 
treated with crizotinib and responded clinically. The duration 
of response varied significantly, from only 2 weeks to over 1.5 
years. As has been previously described,23 the central nervous 
system was the site of first progression under crizotinib in a 
significant proportion of these patients. Low cerebral spinal 
fluid concentrations of crizotinib have been described as a 
possible cause of this pattern of progression.24
This study used preselection based on clinical criteria to 
increase the yield of screening for the EML4-ALK transloca-
tion in a cohort of patients with advanced NSCLC in Germany. 
Even within the study cohort, which was enriched for younger 
patients, nonsmokers, and women, ALK-positive patients were 
characterized by significantly fewer pack-years smoking his-
tory and tended to be somewhat younger than ALK-negative 
patients. Interestingly, we found that the ALK-positive patients 
had also received significantly more lines of treatment over 
longer periods of time before ALK testing. Particularly pro-
longed periods of PFS were observed in response to peme-
trexed, vinorelbine, and cetuximab. All ALK-positive patients 
in this cohort showed clinically significant responses to treat-
ment with crizotinib. An ongoing project at our institution is 
seeking to better characterize tumors harboring EML4-ALK 
fusion both at a molecular and clinical level.
Although testing for ALK translocations in all patients 
with EGFR wild-type adenocarcinoma is an important goal, 
in many regions it is not yet a reality. Although we do not pro-
pose excluding patients from ALK testing based on clinical 
criteria, clinical preselection of those patients most likely to 
harbor ALK translocations may facilitate the referral of these 
patients to centers able to offer testing. In particular, in areas 
not yet able to test all patients for ALK translocations, the 
selection of patients based on exceptionally long responses to 
multiple lines of systemic therapy may increase the yield of 
ALK testing.
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